Efficacy of Intravenous Levetiracetam in Neonatal Seizures: A Phase 2 Randomized Blinded Controlled Study of the Efficacy of Intravenous Levetiracetam (LEV) as First Line Treatment for Neonatal Seizures
Latest Information Update: 26 Nov 2022
At a glance
- Drugs Levetiracetam (Primary) ; Phenobarbital sodium
- Indications Neonatal seizures
- Focus Therapeutic Use
- Acronyms NEOLEV-2
- 18 Nov 2022 According to a Sun Pharmaceutical Industries media release, the U.S. Food and Drug Administration (US FDA) has approved SEZABY™ (phenobarbital sodium powder for injection) for the treatment of neonatal seizures based on the results of this trial.
- 08 May 2020 Primary endpoint has been met. (Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg))
- 08 May 2020 Results assessing efficacy Levetiracetam Versus Phenobarbital for Neonatal Seizures, published in the Pediatrics